Fibroblast growth factor 21 – a key player in cardiovascular disorders?

Lenart-Lipińska, Monika; Duma, D; Hałabiś, Magdalena; Dziedzic, Marcin; Solski, Janusz

doi:10.1515/hmbci-2016-0026

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGF-21 is produced by muscle fibers, and studies have shown that it improves skeletal muscle function [ 19 ], although FGF-21 is also produced by cardiomyocytes in a response to various stress factors [ 11 ]. Based on research data on the cardioprotective effect of this cardiomyokine, it can be hypothesized that FGF-21 may play a clinical role in inhibiting the pathogenesis of AS [ 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…FGF-21 exerts cardioprotective effects, e.g., against cardiac hypertrophy and cardiac inflammation [ 11 ]. Data suggest that the blood levels of FGF-21 are associated with increased cardiovascular risk [ 12 ]. Our previous study found that circulating concentrations of FGF-21 have also been increased in AS patients without coronary and peripheral atherosclerosis [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Aortic valve stenosis (AS) develops with a pronounced local inflammatory response, where a variety of growth factors are involved in the process, and may have a pro-inflammatory and anti-inflammatory effect. The aim of our study was to elucidate whether circulating growth factors: growth differentiation factor 15 (GDF-15), angiopoietin-2 (Ang-2), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2), and fibroblast growth factor 21 (FGF-21) could be proposed as clinically relevant biomarkers to improve risk stratification in AS patients. Materials and Methods: AS patients were classified into three groups: 16 patients with mild AS stenosis; 19 with moderate and 11 with severe AS, and 30 subjects without AS (echocardiographically approved) were selected as a control group. GDF-15, Ang-2, VEGF-A, FGF-2, and FGF-21 were measured in plasma by the ELISA method. Results: GDF-15 levels differed significantly not only when comparing AS patients with control groups (p < 0.0001), but also a statistically significant difference was achieved when comparing AS patients at a mild degree stage with control individuals. We found a strong relationship of GDF-15 levels regarding AS severity degree (p < 0.0001). VEGF-A, FGF-2 and FGF-21 levels were significantly higher in AS patients than in controls, but relationships regarding the AS severity degree were weaker (p < 0.02). ROC analysis of the study growth factors showed that GDF-15 might serve as a specific and sensitive biomarker of AS stenosis (AUC = 0.75, p = 0.0002). FGF-21 correlated with GDF-15, Ang-2, and FGF-2, but it did not reach the level to serve as a clinically relevant biomarker of AS stenosis. Conclusions: AS is associated with significantly increased GDF-15, VEGF-A, FGF-2, and FGF-21 levels in plasma, but only GDF-15 shows a pronounced relationship regarding AS severity degree, and GDF-15 might serve as a specific and sensitive biomarker of AS stenosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Fibroblast growth factor 21 (FGF21) is mainly produced and secreted by the liver and adipose tissue, which acts as an endocrine-like cytokine in glucose, lipid and energy metabolism [ 1 ]. Recent studies have also revealed that circulating FGF21 levels are elevated in several metabolic abnormalities [ 2 , 3 ]. In addition, it also increases progressively as renal function declines [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study

Li,

Jiang,

Zhang

et al. 2023

Renal Failure

View full text Add to dashboard Cite

Introduction: We explored the relationship and the predictive value of serum fibroblast growth factor 21 (FGF21) with all-cause mortality, major adverse cardiovascular events (MACEs) and pneumonia in hemodialysis (HD) patients. Methods: A total of 388 Chinese HD patients from two HD centers were finally enrolled in this prospective cohort study (registration number: ChiCTR 1900028249) between January 2018 and December 2018. Serum FGF21 was detected. Patients were followed up with a median period of 47 months to record the MACEs and pneumonia until death or 31 December 2022. Results: The incidence of all-cause mortality, MACEs and pneumonia in HD patients were 20.6%, 29.6%, and 34.8%, respectively. The optimal cutoffs for FGF21 to predict all-cause mortality, MACEs and pneumonia were 437.57 pg/mL, 216.99 pg/mL and 112.79 pg/mL. Multivariate Cox regression analyses showed that FGF21, as a categorical variable, was an independent predictor for all-cause mortality, MACEs and pneumonia (HR, 3.357, 95% CI, 2.128–5.295, p < 0.001; HR, 1.575, 95% CI, 1.046–2.371, p = 0.029; HR, 1.784; 95% CI, 1.124–2.830; p = 0.014, respectively). The survival nomogram, MACEs-free survival nomogram and pneumonia-free survival nomogram based on FGF21 constructed for individualized assessment of HD patients had a high C-index with 0.841, 0.706 and 0.734. Conclusion: Higher serum FGF21 is an independent predictor of all-cause mortality, MACEs and pneumonia in HD patients.

show abstract

“…Studies confirm that growth differentiation factor 15 (GDF-15), angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), and fibroblast growth factor 2 (FGF-2) are implicated in inflammation and angiogenesis [13][14][15]. Anti-inflammatory growth factor fibroblast growth factor 21 (FGF21) is also of clinical importance [16,17]. Metalloproteinase (MMP)-9 is involved in the pathogenesis of AS [18,19].…”

Section: Introductionmentioning

confidence: 99%

Thioredoxin-1 and Correlations of the Plasma Cytokines Regarding Aortic Valve Stenosis Severity

et al. 2021

View full text Add to dashboard Cite

Aortic valve stenosis (AS) develops not only with a pronounced local inflammatory response, but also oxidative stress is involved. The aim of this study was to evaluate the plasma levels of thioredoxin-1 (TRX1), myeloperoxidase (MPO), chemerin, growth differentiation factor 15 (GDF-15), angiopoietin-2 (Ang-2), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2), fibroblast growth factor 21 (FGF-21), and metalloproteinase (MMP)-1, -3, and -9 in acquired AS patients as well as to clarify the correlations of TXR1 and the plasma inflammatory biomarkers regarding AS severity. AS patients were classified into three groups: 16 patients with mild AS stenosis, 19 with moderate and 11 with severe AS, and 30 subjects without AS were selected as a control group. AS patients had significantly higher plasma levels of TRX1 compared to controls, but the highest difference was found in mild AS patients compared to the controls. We conclude that AS is associated with significantly increased plasma TRX1 levels, and TRX1 might serve as a specific and sensitive biomarker of AS. TRX1 and also chemerin, GDF-15, VEGF-A, FGF-2 and FGF-21 significantly correlate with AS severity degrees. TRX1 also showed positive association with FGF-2, VEGF-A, and MMP-3 in all AS patients.

show abstract

Fibroblast growth factor 21 – a key player in cardiovascular disorders?

Cited by 4 publications

References 21 publications

Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study

Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study

Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study

Thioredoxin-1 and Correlations of the Plasma Cytokines Regarding Aortic Valve Stenosis Severity

Contact Info

Product

Resources

About